A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced or Metastatic Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Research Site · Phoenix, AZ
California · 1
- Research Site · Santa Rosa, CA
Florida · 1
- Research Site · Jacksonville, FL
Maryland · 1
- Research Site · Baltimore, MD
Minnesota · 1
- Research Site · Rochester, MN
Ohio · 1
- Research Site · Cleveland, OH
Rhode Island · 1
- Research Site · Providence, RI
Texas · 1
- Research Site · Tyler, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.